The new U.S.-U.K. pharmaceutical agreement is an important reminder that there is a smarter way to address global drug-pricing disparities than by importing artificial price controls into the United States. If the goal is to make medicines more affordable without undermining the innovation pipeline, trade policy that pressures foreign governments to pay more for the research and development they benefit from is far preferable to Most Favored Nation-style pricing rules that cap what Americans pay by reference to the lowest foreign price.
At its core, this debate is about who funds the extraordinary cost of pharmaceutical innovation. The United States has long shouldered a disproportionate share of that burden, in part because other wealthy nations have used reference pricing, reimbursement controls, and rebate systems that keep their prices low while allowing their patients to benefit from American-led innovation. The Trump administration’s deal with the United Kingdom moves in the opposite direction from MFN: instead of forcing U.S. prices down to European levels, it pushes a major trading partner to pay more for new medicines and to reduce the hidden clawbacks and rebate demands that have distorted access and discouraged investment.